A Multicenter Long-Term Study of Imatinib Treatment for Japanese Patients With Unresectable or Recurrent Gastrointestinal Stromal Tumors

作者：Ogata Kyoichi^*; Mochiki Erito; Ojima Hitoshi; Haga Norihiro; Fukuchi Minoru; Aihara Ryuusuke; Ando Hiroyuki; Uchida Nobuyuki; Toyomasu Yoshitaka; Suzuki Masaki; Kimura Akiharu; Kogure Norimichi; Yokobori Takehiko; Ohno Tetsuro; Kuwano Hiroyuki

来源：Journal of Surgical Oncology, 2014, 110(8): 942-946.

DOI：10.1002/jso.23773

• GIST
• imatinib
• recurrence

Background and ObjectivesThis multicenter study, which was conducted in northern Kanto, Japan, aimed to assess the efficacy of imatinib mesylate against advanced or recurrent gastrointestinal stromal tumors (GIST). %26lt;br%26gt;MethodsThe clinicopathological data of 234 GIST patients who were treated at one of the 11 participating hospitals from 2001-2011 were retrospectively reviewed. Imatinib was administered as a first-line therapy in cases involving unresectable disease or postoperative recurrence (41 cases). The median follow-up period was 4.0 years. %26lt;br%26gt;ResultsAfter a median follow-up period of 4.0 years, the patients treated with imatinib (n=41) exhibited 1-, 3-, and 5-year overall survival (OS) rates of 92.3%, 74.9%, and 53.8%, respectively. In univariate and multivariate analyses, imatinib dose reduction and achieving a complete or partial response were found to be associated with increased OS. %26lt;br%26gt;ConclusionsLong-term imatinib treatment is recommended for patients with non-progressive disease. If patients experience significant toxicities, temporary dose reduction might be useful. J. Surg. Oncol. 2014; 110:942-946.

• 出版日期2014-12-15